Search

Your search keyword '"Phillips, Tycel J."' showing total 260 results
Start Over Author "Phillips, Tycel J."
260 results on '"Phillips, Tycel J."'

2. Integrative analysis of clinicopathological features defines novel prognostic models for mantle cell lymphoma in the immunochemotherapy era: a report from The North American Mantle Cell Lymphoma Consortium

Author

Vose, Julie M., Fu, Kai, Wang, Lu, Mansoor, Adnan, Stewart, Douglas, Cheng, Hongxia, Smith, Lynette, Yuan, Ji, Qureishi, Hina Naushad, Link, Brian K., Cessna, Melissa H., Barr, Paul M., Kahl, Brad S., Mckinney, Matthew S., Khan, Nadia, Advani, Ranjana H., Martin, Peter, Goy, Andre H., Phillips, Tycel J., Mehta, Amitkumar, Kamdar, Manali, Crump, Michael, Pro, Barbara, Flowers, Christopher R., Jacobson, Caron A., Smith, Sonali M., Stephens, Deborah M., Bachanova, Veronika, Jin, Zhaohui, Wu, Shishou, Hernandez-Ilizaliturri, Francisco, Torka, Pallawi, Anampa-Guzmán, Andrea, Kashef, Farshid, Li, Xing, Sharma, Sunandini, Greiner, Timothy C., Armitage, James O., Lunning, Matthew, Weisenburger, Dennis D., Bociek, Robert G., Iqbal, Javeed, Yu, Guohua, and Bi, Chengfeng

Published
2023
Full Text
View/download PDF

10. The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 study.

Author

Zelenetz, Andrew D., Jurczak, Wojciech, Ribrag, Vincent, Linton, Kim, Collins, Graham P., Jiménez, Javier L., Bishton, Mark, Dholaria, Bhagirathbhai, Mengarelli, Andrea, Phillips, Tycel J., Sungala, Nagendraprasad, Musuraca, Gerardo, Sheehy, Oonagh, Van Den Neste, Eric, Odera, Mitsuhiko, Miao, Lu, Gold, Daniel P., Ghalie, Richard G., and Zinzani, Pier L.

Published
2024
Full Text
View/download PDF

12. Consensus Recommendations on the Management of Toxicity Associated with CD3xCD20 Bispecific Antibody Therapy

Author

Crombie, Jennifer L., primary, Graff, Tara, additional, Falchi, Lorenzo, additional, Karimi, Yasmin H., additional, Bannerji, Rajat, additional, Nastoupil, Loretta J, additional, Thieblemont, Catherine, additional, Ursu, Renata, additional, Bartlett, Nancy L., additional, Nachar, Victoria R, additional, Weiss, Jonathan, additional, Osterson, Jane, additional, Patel, Krish, additional, Brody, Joshua D., additional, Abramson, Jeremy S, additional, Lunning, Matthew A, additional, Shah, Nirav N., additional, Ayed, Ayed, additional, Kamdar, Manali, additional, Parsons, Benjamin M., additional, Caimi, Paolo, additional, Flynn, Ian W., additional, Herrera, Alex F., additional, Sharman, Jeff P., additional, McKenna, Marshall, additional, Armand, Philippe, additional, Kahl, Brad S., additional, Smith, Sonali M, additional, Zelenetz, Andrew D, additional, Budde, Lihua E, additional, Hutchings, Martin, additional, Phillips, Tycel J., additional, and Dickinson, Michael, additional

Published
2024
Full Text
View/download PDF

19. Long‐term outcomes of second‐line versus later‐line zanubrutinib treatment in patients with relapsed/refractory mantle cell lymphoma: An updated pooled analysis

Author

Song, Yuqin, primary, Zhou, Keshu, additional, Zou, Dehui, additional, Li, Dengju, additional, Hu, Jianda, additional, Yang, Haiyan, additional, Zhang, Huilai, additional, Ji, Jie, additional, Xu, Wei, additional, Jin, Jie, additional, Lv, Fangfang, additional, Feng, Ru, additional, Gao, Sujun, additional, Zhou, Daobin, additional, Tam, Constantine S., additional, Simpson, David, additional, Wang, Michael, additional, Phillips, Tycel J., additional, Opat, Stephen, additional, Fang, Cheng, additional, Sun, Shaohui, additional, and Zhu, Jun, additional

Published
2023
Full Text
View/download PDF

26. Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1

Author

Batlevi, Connie Lee, primary, Salles, Gilles, additional, Park, Steven I., additional, Phillips, Tycel J., additional, Amengual, Jennifer E., additional, Andorsky, David, additional, Campbell, Philip, additional, McKay, Pamela, additional, Leonard, John P., additional, Sondhi, Manu, additional, Chen, Yingxue, additional, Slatcher, Pamela L., additional, Lin, Richard, additional, Szanto, Attila, additional, Abbadi, Sara, additional, and Morschhauser, Franck, additional

Published
2022
Full Text
View/download PDF

27. Long-Term Outcomes of Second-Line Vs Later-Line Zanubrutinib Treatment in Patients with Relapsed/Refractory MCL: An Updated Pooled Analysis

Author

Song, Yuqin, primary, Zhou, Keshu, additional, Zou, Dehui, additional, Li, Dengju, additional, Hu, Jianda, additional, Yang, Haiyan, additional, Zhang, Huilai, additional, Ji, Jie, additional, Xu, Wei, additional, Jin, Jie, additional, Lv, Fangfang, additional, Feng, Ru, additional, Gao, Sujun, additional, Zhou, Daobin, additional, Tam, Constantine S., additional, Simpson, David, additional, Wang, Michael L., additional, Phillips, Tycel J., additional, Opat, Stephen, additional, Fang, Cheng, additional, Sun, Shaohui, additional, and Zhu, Jun, additional

Published
2022
Full Text
View/download PDF

28. Efficacy and Safety of Single-Agent Zandelisib Administered By Intermittent Dosing in Patients with Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Final Results of the Tidal Phase 2 Study

Author

Zelenetz, Andrew D., primary, Jurczak, Wojciech, additional, Ribrag, Vincent, additional, Linton, Kim M., additional, Collins, Graham P., additional, Bishton, Mark, additional, López Jiménez, Javier, additional, Dholaria, Bhagirathbhai, additional, Mengarelli, Andrea, additional, Phillips, Tycel J., additional, Sungala, Nagendra Prasad, additional, Chan, Henry, additional, Musuraca, Gerardo, additional, Sheehy, Oonagh, additional, Yan, Junyi, additional, Xu, Weiming, additional, Azoulay, Michel, additional, and Zinzani, Pier Luigi, additional

Published
2022
Full Text
View/download PDF

29. Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Author

Phillips, Tycel J., primary, Dickinson, Michael, additional, Morschhauser, Franck, additional, Bachy, Emmanuel, additional, Crump, Michael, additional, Trněný, Marek, additional, Bartlett, Nancy L., additional, Zaucha, Jan, additional, Wrobel, Tomasz, additional, Offner, Fritz, additional, Humphrey, Kathryn, additional, Lundberg, Linda, additional, Relf, James, additional, Filézac de L'Étang, Audrey, additional, Carlile, David, additional, Byrne, Ben, additional, Qayum, Naseer, additional, and Carlo-Stella, Carmelo, additional

Published
2022
Full Text
View/download PDF

31. Closing the Gap: Implementation of a Novel Interactive Virtual Tumor Board to Improve Expert Knowledge Sharing in Malignant Hematology

Author

Ciuro, Jordan, primary, Henry, Elizabeth, additional, Housri, Nadine, additional, Banerjee, Rahul, additional, Brem, Elizabeth A, additional, Brooks, Taylor, additional, Derman, Ben A., additional, Hill, Brian T., additional, Hofmeister, Craig C, additional, Lunning, Matthew A., additional, Matasar, Matthew J., additional, Phillips, Tycel J., additional, Rutherford, Sarah C., additional, Zanwar, Saurabh, additional, and Lee, Lauren E, additional

Published
2022
Full Text
View/download PDF

32. Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study

Author

Woyach, Jennifer A., primary, Flinn, Ian W., additional, Awan, Farrukh T., additional, Eradat, Herbert, additional, Brander, Danielle, additional, Tees, Michael, additional, Parikh, Sameer A., additional, Phillips, Tycel J., additional, Ghori, Razi, additional, Reddy, Nishitha M., additional, Farooqui, Mohammed Z.H., additional, Byrd, John C., additional, and Stephens, Deborah M., additional

Published
2022
Full Text
View/download PDF

33. A Phase 1 Study of Plamotamab, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma: Recommended Dose Safety/Efficacy Update and Escalation Exposure-Response Analysis

Author

Patel, Krish, primary, Riedell, Peter A., additional, Tilly, Hervé, additional, Ahmed, Sairah, additional, Michot, Jean-Marie, additional, Ghesquieres, Herve, additional, Schiano de Collela, Jean Marc, additional, Chanan-Khan, Asher, additional, Bouabdallah, Kamal, additional, Tessoulin, Benoit, additional, Iyengar, Sunil, additional, Long, Meixiao, additional, Clynes, Raphael, additional, Kanodia, Jitendra, additional, Bao, Lei, additional, Ding, Ying, additional, Jin, Jianhua, additional, Ainsworth, William B, additional, Garcha, Raman, additional, Kye, Steve, additional, and Phillips, Tycel J., additional

Published
2022
Full Text
View/download PDF

36. Contributors

Author

Abdullahi, Hamisu, Abubakar, Sharafudeen Dahiru, Aliyu, Mansur, Anka, Abubakar Umar, Azizi, Gholamreza, Bagacean, Cristina, Bonavida, Benjamin, Bordron, Anne, Bouallegui, Emna, Brando, Bruno, Cavallo, Federica, Chen, Qing, Chen, Tao-xiang, Cho, William C.S., Clerico, Michele, Dadkhahfar, Sahar, dos Santos, Rafael Pinheiro, Fan, Yuan-teng, Furie, Richard, Gatti, Arianna, Glass, Thomas R., Grier, Madelynn, Gurney, Mark, Ihim, Stella Amarachi, Jin, Yanling, Jin, Ying, Kannan, Lakshmi, Khan, Mohammad Aqueel, Litzow, Mark R., Liu, Yu-min, Maleknia, Shayan, McBride, Helen J., Montoto, Silvia, Morel, Marie, Panwar, Umesh, Peng, Bi-wen, Phillips, Tycel J., Qin, Ran, Ragaini, Simone, Saffarioun, Mohammad, Selvaraj, Chandrabose, Singh, Sanjeev Kumar, Snyder, Matthew Salvatore, Song, Guoqi, Takiar, Radhika, Veloso, Marcelo Antônio Oliveira Santos, Wang, Cheng, Wang, Jing, Xia, Bili, Xu, Jianqing, Yang, Li, and Zian, Zeineb

Published
2024
Full Text
View/download PDF

37. ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

Author

Janakiram, Murali, primary, Depaus, Julien, additional, Wagner-Johnston, Nina, additional, Zinzani, Pier Luigi, additional, Phillips, Tycel J., additional, Maly, Joseph, additional, Ferrari, Silvia, additional, Bryan, Locke J., additional, Delwail, Vincent, additional, de Guibert, Sophie, additional, Tani, Monica, additional, Dai, Vivian, additional, Havenith, Karin, additional, Boni, Joseph, additional, He, Xiaomin, additional, Ervin-Haynes, Annette, additional, and Carlo-Stella, Carmelo, additional

Published
2021
Full Text
View/download PDF

38. Poster: ABCL-339: Clinical Activity of Loncastuximab Tesirine (Lonca) Plus Ibrutinib in Non-Hodgkin Lymphoma: Updated LOTIS-3 Phase 1 Results

Author

Janakiram, Murali, primary, Depaus, Julien, additional, Wagner-Johnston, Nina, additional, Zinzani, Pier Luigi, additional, Phillips, Tycel J., additional, Maly, Joseph, additional, Ferrari, Silvia, additional, Bryan, Locke J., additional, Delwail, Vincent, additional, De Guibert, Sophie, additional, Tani, Monica, additional, Dai, Vivian, additional, Havenith, Karin, additional, Boni, Joseph, additional, He, Xiaomin, additional, Ervin-Haynes, Annette, additional, and Carlo-Stella, Carmelo, additional

Published
2021
Full Text
View/download PDF

42. Evaluating Acalabrutinib In The Treatment Of Mantle Cell Lymphoma: Design, Development, And Place In Therapy

Author

Girard, Jennifer, Reneau, John, Devata, Sumana, Wilcox, Ryan A, Kaminski, Mark S, Mercer, Jessica, Carty, Shannon, and Phillips, Tycel J

Subjects
immune system diseases, Bruton’s tyrosine kinase, combinations, hemic and lymphatic diseases, mantle cell lymphoma, Review, long-term safety
Abstract

Mantle cell lymphoma (MCL) is an incurable intermediate-grade lymphoma representing 5–6% of non-Hodgkin’s lymphomas diagnosed in the United States. The introduction of inhibitors of Bruton’s tyrosine kinase (BTK) into targeted therapy for MCL has significantly improved outcomes in patients with relapsed/refractory (R/R) disease. Since the initial approval of the first-generation inhibitor, ibrutinib, several second-generation inhibitors have been explored. Acalabrutinib, a second-generation BTK inhibitor, has demonstrated impressive efficacy in clinical trials along with a safety profile that thus far appears improved compared to ibrutinib. The results of a Phase II trial in patients with R/R MCL led to the approval of acalabrutinib in this patient population while fueling further exploration of acalabrutinib in several ongoing clinical trials.

Published
2019

43. Additional file 1 of Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials

Author

Zhou, Keshu, Zou, Dehui, Zhou, Jianfeng, Hu, Jianda, Yang, Haiyan, Zhang, Huilai, Ji, Jie, Xu, Wei, Jin, Jie, Lv, Fangfang, Feng, Ru, Gao, Sujun, Zhou, Daobin, Tam, Constantine S., Simpson, David, Wang, Michael, Phillips, Tycel J., Opat, Stephen, Huang, Zhiyue, Lu, Huafei, Song, Yuqin, and Song, Yongping

Abstract

Additional file 1. Supplementary methods. Table S1. Baseline covariates before and after weighting. Table S2. Prior medication uses after weighting. Table S3. Treatment emergent AEs (any grade, grade 3 or higher). Figure S1. Outcomes of patients with R/R MCL treated with zanubrutinib in the BGB-3111-AU-003 and BGB-3111-206 trial. (A) DOR in the BGB-3111-AU-003. (B) PFSin the BGB-3111-AU-003. (C) OS in the BGB-3111-AU-003. (D) DOR in the BGB-3111-206. (E) PFS in the BGB-3111-206. (F) OS in the BGB-3111-206. Figure S2. Outcomes of patients with R/R MCL treated with zanubrutinib. (A) DOR. (B) PFS. (C) OS. Figure S3. Outcomes of patients with R/R MCL treated with zanubrutinibas second- versus later-line therapy. (A) DOR before weighting. (B) PFS before weighting. (C) OS before weighting. (D) DOR after weighting. (E) PFS after weighting. (F) OS after weighting.

Published
2021
Full Text
View/download PDF

45. Burkitt Lymphoma International Prognostic Index

Author

Olszewski, Adam J., primary, Jakobsen, Lasse H., additional, Collins, Graham P., additional, Cwynarski, Kate, additional, Bachanova, Veronika, additional, Blum, Kristie A., additional, Boughan, Kirsten M., additional, Bower, Mark, additional, Dalla Pria, Alessia, additional, Danilov, Alexey, additional, David, Kevin A., additional, Diefenbach, Catherine, additional, Ellin, Fredrik, additional, Epperla, Narendranath, additional, Farooq, Umar, additional, Feldman, Tatyana A., additional, Gerrie, Alina S., additional, Jagadeesh, Deepa, additional, Kamdar, Manali, additional, Karmali, Reem, additional, Kassam, Shireen, additional, Kenkre, Vaishalee P., additional, Khan, Nadia, additional, Kim, Seo-Hyun, additional, Klein, Andreas K., additional, Lossos, Izidore S., additional, Lunning, Matthew A., additional, Martin, Peter, additional, Martinez-Calle, Nicolas, additional, Montoto, Silvia, additional, Naik, Seema, additional, Palmisiano, Neil, additional, Peace, David, additional, Phillips, Elizabeth H., additional, Phillips, Tycel J., additional, Portell, Craig A., additional, Reddy, Nishitha, additional, Santarsieri, Anna, additional, Sarraf Yazdy, Maryam, additional, Smeland, Knut B., additional, Smith, Scott E., additional, Smith, Stephen D., additional, Sundaram, Suchitra, additional, Zayac, Adam S., additional, Zhang, Xiao-Yin, additional, Zhu, Catherine, additional, Cheah, Chan Y., additional, El-Galaly, Tarec C., additional, and Evens, Andrew M., additional

Published
2021
Full Text
View/download PDF

46. Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Author

Salles, Gilles, Tilly, Hervé, Chaidos, Aristeidis, McKay, Pam, Phillips, Tycel J., Assouline, Sarit E, Batlevi, Connie Lee, Campbell, Philip, Ribrag, Vincent, Damaj, Gandhi Laurent, Dickinson, Michael, Jurczak, Wojciech, Kaźmierczak, Maciej, Opat, Stephen, Radford, John A., Schmitt, Anna, Whalen, Jennifer, Hamlett, Anthony, Kamp, Beth, Adib, Deyaa, and Morschhauser, Franck

Published
2020
Full Text
View/download PDF

47. The Burkitt Lymphoma International Prognostic Index (BL-IPI)

Author

Olszewski, Adam J, Jakobsen, Lasse H., Collins, Graham P., Cwynarski, Kate, Bachanova, Veronika, Blum, Kristie A., Boughan, Kirsten M, Bower, Mark, Dalla Pria, Alessia, Danilov, Alexey, David, Kevin A., Diefenbach, Catherine, Ellin, Fredrik, Epperla, Narendranath, Farooq, Umar, Feldman, Tatyana A., Gerrie, Alina S., Jagadeesh, Deepa, Kamdar, Manali, Karmali, Reem, Kassam, Shireen, Kenkre, Vaishalee P., Khan, Nadia, Klein, Andreas, Lossos, Izidore S., Lunning, Matthew A., Martin, Peter, Martinex-Calle, Nicolas, Montoto, Silvia, Naik, Seema, Palmisiano, Neil, Peace, David, Phillips, Elizabeth H, Phillips, Tycel J., Portell, Craig A., Reddy, Nishitha, Santarsieri, Anna, Yazdy, Maryam Sarraf, Smeland, Knut B., Smith, Scott E., Smith, Stephen D., Sundaram, Suchitra, Venugopal, Parameswaran, Zayac, Adam, Zhang, Xiao-Yin, Zhu, Catherine, Cheah, Chan Yoon, El-Galaly, Tarec Christoffer, and Evens, Andrew M.

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results